Metformin reduces the risk of developing influenza A virus related cardiovascular disease
Han Sol Lee, Ji Yun Noh, Joon Young Song, Hee Jin Cheong, Woo Joo Kim
Heliyon, doi:10.1016/j.heliyon.2023.e20284
A C T This study investigated the drug repositioning potential of metformin for cardiovascular risk due to influenza A virus infection. Statistical analysis was performed to analyze factors related to the risk of death after IAV infection in diabetic patients. Through in vitro and in vivo experiments, the effect of metformin on influenza A virus infection in non-diabetic conditions was analyzed. In logistic regression analysis, influenza vaccination (OR = 0.378, p-value = 0.007, 0.186 < 95% C⋅I < 0.768) and metformin treatment (OR = 0.380, p-value = 0.016, 0.173 < 95% C⋅I < 0.835) were associated with a decreased influenza-related mortality in diabetic patients. In vitro and in vivo studies showed that viral replication and influenza A virus-induced cytokine expression were inhibited by metformin. In particular, MCP-1 and IP-10, cytokines related to cell infiltration and cardiovascular disease development, were significantly reduced by metformin under influenza A virus infection condition. As a result, the acute exacerbation of atherosclerosis caused by influenza A virus in mouse aorta was inhibited by metformin. In addition, we found that regulation of AKT/MAPK signaling plays an important role in the mechanism of metformin. In conclusion, we demonstrated the potential and mechanism of metformin as a treatment for acute exacerbation of atherosclerosis caused by influenza A virus infection.
Heliyon 9 (2023) e20284
Author contribution statement Han Sol Lee: Conceived and designed the experiments; Performed the experiments; Contributed reagents, materials, analysis tools or data; Wrote the paper. Woo Joo Kim: Conceived and designed the experiments; Contributed reagents, materials, analysis tools or data; Wrote the paper. Ji Yun Noh, Joon Young Song, Hee Jin Cheong: Analyzed and interpreted the data.
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2023.e20284.
References
References
Abdel Monem, Farid, Abbassi, Youssry, Andraues et al., The potential hepatoprotective effect of metformin in hepatitis C virus-infected adolescent patients with beta thalassemia major: randomised clinical trial, Int. J. Clin. Pract,
doi:10.1111/ijcp.14104Amoani, Sakyi, Mantey, Laing, Ephraim et al., Increased metformin dosage suppresses proinflammatory cytokine levels in systemic circulation and might contribute to its beneficial effects, J. Immunoassay Immunochem,
doi:10.1080/15321819.2020.1862861Benjamin, Virani, Callaway, Chamberlain, Chang et al., American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2018 update: a report from the American heart association, Circulation,
doi:10.1161/CIR.0000000000000558Bramante, Ingraham, Murray, Marmor, Hovertsen et al., Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis, Lancet Healthy Longev,
doi:10.1016/S2666-7568(20)30033-7Chen, Liu, Ye, Effects of metformin on blood and urine pro-inflammatory mediators in patients with type 2 diabetes, J. Inflamm,
doi:10.1186/s12950-016-0142-3Chen, Wang, Liu, Su, Zhang et al., IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19, Mol. Med,
doi:10.1186/s10020-020-00230-xDing, Zhou, Long, Chen, Zhao et al., DUSP8 phosphatase: structure, functions, expression regulation and the role in human diseases, Cell Biosci,
doi:10.1186/s13578-019-0329-4Dragomir, Simionescu, Monocyte chemoattractant protein-1-a major contributor to the inflammatory process associated with diabetes, Arch. Physiol. Biochem,
doi:10.1080/13813450601094672Farfan-Morales, Cordero-Rivera, Osuna-Ramos, Monroy-Muñoz, De Jesús-González et al., The antiviral effect of metformin on zika and dengue virus infection, Sci. Rep,
doi:10.1038/s41598-021-87707-9Fey, Croucher, Kolch, Kholodenko, Crosstalk and signaling switches in mitogen-activated protein kinase cascades, Front. Physiol,
doi:10.3389/fphys.2012.00355Han, Xie, Liu, Gao, Yang et al., Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis, Cardiovasc. Diabetol,
doi:10.1186/s12933-019-0900-7Ko, Fujiwara, Krishnan, Abe, En face preparation of mouse blood vessels, J. Vis. Exp,
doi:10.3791/55460Lang, Raffi, Dual-specificity phosphatases in immunity and infection: an update, Int. J. Mol. Sci,
doi:10.3390/ijms20112710Lee, Noh, Shin, Song, Cheong et al., Matrix metalloproteinase-13 in atherosclerotic plaque is increased by influenza A virus infection, J. Infect. Dis,
doi:10.1093/infdis/jiz580Lexis, Van Der Horst-Schrivers, Lipsic, Valente, Muller Kobold et al., The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial, BMJ Open Diabetes Res Care,
doi:10.1136/bmjdrc-2015-000090Lloyd-Jones, Braun, Ndumele, Smith, Sperling et al., Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American heart association and American College of cardiology, Circulation,
doi:10.1161/CIR.0000000000000638Lopez, Mathers, Ezzati, Jamison, Murray, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data, Lancet,
doi:10.1016/S0140-6736(06)68770-9Luo, Das, Chen, Wu, Li et al., Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management, Cardiovasc. Diabetol,
doi:10.1186/s12933-019-0860-yMatheus, Tannus, Cobas, Palma, Negrato et al., Impact of diabetes on cardiovascular disease: an update, Int. J. Hypertens,
doi:10.1155/2013/653789Mócsai, Ruland, Tybulewicz, The SYK tyrosine kinase: a crucial player in diverse biological functions, Nat. Rev. Immunol,
doi:10.1038/nri2765Saraei, Asadi, Kakar, Moradi-Kor, The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances, Cancer Manag. Res,
doi:10.2147/CMAR.S200059Tsuji, Hashimoto-Hachiya, Yen, Takemura, Yumine et al., Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis, Cell Death Dis,
doi:10.1038/s41420-020-0245-8Yang, Qin, Wang, Meng, Xian et al., Metformin inhibits the NLRP3 inflammasome via AMPK/mTORdependent effects in diabetic cardiomyopathy, Int. J. Biol. Sci,
doi:10.7150/ijbs.29680
